CYD Q3 2020 Earnings Slight EPS Miss Amid Operational Resilience Dermata Therapeutics DRMA Q1 2026 Earnings Narrower Loss Beats Expectations as Pipeline Progress Continues IMA Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Advances Pipeline GURE Q3 2023 Earnings Net Loss of 017 per Share Stock Declines 209 ENLV Q4 2025 Earnings Significant EPS Miss Amid Development Stage Costs ZM Q1 2026 Earnings Strong EPS Beat Amid Revenue Discrepancy Stock Dips